{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:53:15Z","timestamp":1774453995660,"version":"3.50.1"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Particle therapy offers highly precise treatment, reducing damage of surrounding organs while delivering dose to the target areas. The improved therapeutic ratio is largely attributed to the Bragg curve, which demonstrates steep dose fall-off. Although historically pediatric tumors had the clearest benefit, the application of particle therapy has expanded to adult patients of all disease sites, including tumors of the head and neck, central nervous system, thorax, breast, gastrointestinal system, and genitourinary system. As emerging trials provide increasing evidence for the utilization of particle therapy, treatment is becoming more accessible. In addition, radiation technology continues to evolve, and techniques including intensity-modulated proton therapy and adaptive proton therapy are being implemented. We review the evolution of particle therapy, the current clinical evidence supporting its use, and practical considerations.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000822","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:00:39Z","timestamp":1774450839000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Clinical Evidence and Applications of Particle Therapy"],"prefix":"10.1097","volume":"32","author":[{"given":"Anika","family":"Patel","sequence":"first","affiliation":[{"name":"Paul L. Foster School of Medicine, Texas Tech Health Science Center, El Paso, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayeong","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"R1-20260325","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1148\/47.5.487","article-title":"Radiological use of fast protons","volume":"47","author":"Wilson","year":"1946","journal-title":"Radiology"},{"key":"R2-20260325","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0959-8049(97)10044-2","article-title":"Particle beam therapy (hadrontherapy): basis for interest and clinical experience","volume":"34","author":"Orecchia","year":"1998","journal-title":"Eur J Cancer"},{"key":"R3-20260325","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/COC.0b013e3181cdf0fe","article-title":"Basics of particle therapy II biologic and dosimetric aspects of clinical hadron therapy","volume":"33","author":"Rong","year":"2010","journal-title":"Am J Clin Oncol"},{"issue":"S2","key":"R4-20260325","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF03038890","article-title":"Proton therapy for tumors of the skull base","volume":"175","author":"Munzenrider","year":"1999","journal-title":"Strahlenther Onkol"},{"key":"R5-20260325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM198308043090503","article-title":"Bragg-Peak proton-beam therapy for arteriovenous malformations of the brain","volume":"309","author":"Kjellberg","year":"1983","journal-title":"N Eng J Med"},{"key":"R6-20260325","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/00016926009172547","article-title":"Lesions in the depth of the brain produced by a beam of high energy protons","volume":"54","author":"Leksell","year":"1960","journal-title":"Acta Radiol"},{"key":"R7-20260325","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/PPO.0b013e3181b6d4b7","article-title":"Proton beam therapy in pediatric oncology","volume":"15","author":"Merchant","year":"2009","journal-title":"Cancer J"},{"key":"R8-20260325","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","article-title":"Proton therapy\u2014present and future","volume":"109","author":"Mohan","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"R9-20260325","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.semradonc.2006.04.008","article-title":"Radiation therapy with charged particles","volume":"16","author":"Schulz-Ertner","year":"2006","journal-title":"Semin Radiat Oncol"},{"key":"R10-20260325","doi-asserted-by":"crossref","first-page":"20200172","DOI":"10.1259\/bjr.20200172","article-title":"The 20th Gray lecture 2019: health and heavy ions","volume":"93","author":"Blakely","year":"2020","journal-title":"Br J Radiol"},{"key":"R11-20260325","doi-asserted-by":"crossref","first-page":"20200183","DOI":"10.1259\/bjr.20200183","article-title":"Particle therapy in the future of precision therapy","volume":"93","author":"Schaub","year":"2020","journal-title":"Br J Radiol"},{"key":"R12-20260325","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S1470-2045(24)00664-8","article-title":"Innovative, early-phase clinical trials of drug\u2013radiotherapy combinations","volume":"26","author":"Levy","year":"2025","journal-title":"Lancet Oncol"},{"key":"R13-20260325","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3390\/cancers17121980","article-title":"New approaches in radiotherapy","volume":"17","author":"Webster","year":"2025","journal-title":"Cancers"},{"key":"R14-20260325","doi-asserted-by":"crossref","first-page":"104046","DOI":"10.1016\/j.ppnp.2023.104046","article-title":"Emerging technologies for cancer therapy using accelerated particles","volume":"131","author":"Graeff","year":"2023","journal-title":"Prog Part Nucl Phys"},{"key":"R15-20260325","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00066-023-02158-7","article-title":"High-LET charged particles: radiobiology and application for new approaches in radiotherapy","volume":"199","author":"Helm","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"R16-20260325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acm2.12225","article-title":"Commissioning of the world\u2019s first compact pencil-beam scanning proton therapy system","volume":"19","author":"Pidikiti","year":"2018","journal-title":"J Appl Clin Med Phys"},{"key":"R17-20260325","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.3390\/ijms252010969","article-title":"Proton radiation therapy: a systematic review of treatment-related side effects and toxicities","volume":"25","author":"Salem","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R18-20260325","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamaoncol.2019.4889","article-title":"Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer","volume":"6","author":"Baumann","year":"2020","journal-title":"JAMA Oncol"},{"key":"R19-20260325","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/pro6.1149","article-title":"A review of proton therapy\u2014current status and future directions","volume":"6","author":"Mohan","year":"2022","journal-title":"Precis Radiat Oncol"},{"key":"R20-20260325","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2021.066","article-title":"Physical and biological characteristics of particle therapy for oncologists","volume":"53","author":"Byun","year":"2021","journal-title":"Cancer Res Treat"},{"key":"R21-20260325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14338\/IJPT-18-00018.1","article-title":"Comparing photon and charged particle therapy using DNA damage biomarkers","volume":"5","author":"Ray","year":"2018","journal-title":"Int J Part Ther"},{"key":"R22-20260325","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijrobp.2021.08.015","article-title":"Mechanisms and review of clinical evidence of variations in relative biological effectiveness in proton therapy","volume":"112","author":"Paganetti","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20260325","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14338\/IJPT-18-00011.1","article-title":"Proton relative biological effectiveness\u2014uncertainties and opportunities","volume":"5","author":"Paganetti","year":"2018","journal-title":"Int J Part Ther"},{"key":"R24-20260325","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijrobp.2016.02.021","article-title":"Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma","volume":"95","author":"Gunn","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-20260325","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2004.09.064","article-title":"Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique","volume":"62","author":"Slater","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20260325","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ijrobp.2014.04.019","article-title":"Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice","volume":"89","author":"Frank","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-20260325","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2012.08.004","article-title":"Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy","volume":"85","author":"Garden","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-20260325","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2024.42.16_suppl.6006","article-title":"Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC)","volume":"42","author":"Frank","year":"2024","journal-title":"J Clin Oncol"},{"key":"R30-20260325","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ijrobp.2025.08.026","article-title":"Primary results for the phase III trial of Toxicity Reduction using Proton Beam Therapy for Oropharyngeal Cancer (TORPEdO; CRUK\/18\/010)","volume":"123","author":"Thomson","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R31-20260325","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaoto.2022.4165","article-title":"Osteoradionecrosis of the jaw following proton radiation therapy for patients with head and neck cancer","volume":"149","author":"Singh","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"R32-20260325","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.radonc.2017.05.006","article-title":"Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer","volume":"123","author":"Zhang","year":"2017","journal-title":"Radiother Oncol"},{"key":"R33-20260325","doi-asserted-by":"crossref","first-page":"110648","DOI":"10.1016\/j.radonc.2024.110648","article-title":"Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: a long-term, multicenter cohort study","volume":"202","author":"Wu","year":"2025","journal-title":"Radiother Oncol"},{"key":"R34-20260325","doi-asserted-by":"crossref","first-page":"e2113205","DOI":"10.1001\/jamanetworkopen.2021.13205","article-title":"Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated proton therapy vs intensity-modulated radiation therapy","volume":"4","author":"Li","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R35-20260325","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ohn.70113","article-title":"Auditory preservation in nasopharyngeal carcinoma: comparison of proton and photon radiotherapy","volume":"174","author":"Lien","year":"2026","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R36-20260325","doi-asserted-by":"crossref","first-page":"653050","DOI":"10.3389\/fonc.2021.653050","article-title":"Mixed photon and carbon-ion beam radiotherapy in the management of non-metastatic nasopharyngeal carcinoma","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"R37-20260325","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1470-2045(14)70268-2","article-title":"Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis","volume":"15","author":"Patel","year":"2014","journal-title":"Lancet Oncol"},{"key":"R38-20260325","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hed.28082","article-title":"Survival, tumor control, and safety outcomes of proton therapy in sinonasal cancer population: a systematic review and meta-analysis","volume":"47","author":"Vasudevan","year":"2025","journal-title":"Head Neck"},{"issue":"3","key":"R39-20260325","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hed.70078","article-title":"Proton therapy for paranasal sinus cancer: clinical outcomes and patterns of failure","volume":"48","author":"Cao","year":"2025","journal-title":"Head Neck"},{"key":"R40-20260325","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.ijrobp.2023.09.037","article-title":"Combined photon and carbon ion radiation therapy for sinonasal malignancies: results of the HIT\u2013SNT prospective phase 2 trial","volume":"118","author":"Weusthof","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R41-20260325","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ijrobp.2005.03.052","article-title":"Proton radiotherapy for orbital rhabdomyosarcoma: Clinical outcome and a dosimetric comparison with photons","volume":"63","author":"Yock","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R42-20260325","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1080\/0284186X.2019.1627412","article-title":"45 GyRBE for group III orbital embryonal rhabdomyosarcoma","volume":"58","author":"Indelicato","year":"2019","journal-title":"Acta Oncol"},{"key":"R43-20260325","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2015.08.008","article-title":"A multidisciplinary orbit-sparing treatment approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa","volume":"95","author":"Holliday","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R44-20260325","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/s12885-025-13986-4","article-title":"Long-term outcomes and prognostic factors of eye-preserving treatment with particle beam radiotherapy for orbital malignancies","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Cancer"},{"key":"R45-20260325","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ijrobp.2016.12.028","article-title":"Multicenter study of carbon-ion radiation therapy for mucosal melanoma of the head and neck: subanalysis of the japan carbon-ion radiation oncology study group (J-CROS) study (1402 HN)","volume":"97","author":"Koto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R46-20260325","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hed.26044","article-title":"Proton therapy for head and neck paragangliomas: a single institutional experience","volume":"42","author":"Kang","year":"2020","journal-title":"Head & Neck"},{"key":"R47-20260325","doi-asserted-by":"crossref","first-page":"109958","DOI":"10.1016\/j.radonc.2023.109958","article-title":"Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer","volume":"190","author":"Friborg","year":"2024","journal-title":"Radiother Oncol"},{"key":"R48-20260325","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/0284186X.2020.1792548","article-title":"Ongoing and future clinical trials in particle therapy in the Nordic countries","volume":"59","author":"Witt Nystr\u00f6m","year":"2020","journal-title":"Acta Oncol"},{"key":"R49-20260325","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12885-021-08473-5","article-title":"Adenoid cystic carcinoma and carbon ion only irradiation (ACCO): study protocol for a prospective, open, randomized, two-armed, phase II study","volume":"21","author":"Lang","year":"2021","journal-title":"BMC Cancer"},{"key":"R50-20260325","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/s12885-022-09564-7","article-title":"A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy \u2013 including photon and proton therapy \u2013 for the treatment of radioresistant tumors: the ETOILE trial","volume":"22","author":"Balosso","year":"2022","journal-title":"BMC Cancer"},{"key":"R51-20260325","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2019.01.009","article-title":"Are further studies needed to justify the use of proton therapy for paediatric cancers of the central nervous system? A review of current evidence","volume":"133","author":"Huynh","year":"2019","journal-title":"Radiother Oncol"},{"key":"R52-20260325","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrneurol.2016.70","article-title":"Proton therapy for paediatric CNS tumours\u2014improving treatment-related outcomes","volume":"12","author":"Gondi","year":"2016","journal-title":"Nat Rev Neurology"},{"key":"R53-20260325","doi-asserted-by":"crossref","first-page":"e27046","DOI":"10.1002\/pbc.27046","article-title":"Proton therapy for central nervous system tumors in children","volume":"65","author":"Ladra","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R54-20260325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/5879723","article-title":"Proton versus photon radiotherapy for pediatric central nervous system malignancies: a systematic review and meta-analysis of dosimetric comparison studies","volume":"2019","author":"Carbonara","year":"2019","journal-title":"J Oncol"},{"key":"R55-20260325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-023-04510-4","article-title":"The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review","volume":"167","author":"Wilson","year":"2024","journal-title":"J Neurooncol"},{"key":"R56-20260325","doi-asserted-by":"crossref","first-page":"893855","DOI":"10.3389\/fonc.2022.893855","article-title":"Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors: a systematic review and meta-analysis","volume":"12","author":"Upadhyay","year":"2022","journal-title":"Front Oncol"},{"key":"R57-20260325","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S1470-2045(24)00585-0","article-title":"Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial","volume":"25","author":"Vora","year":"2024","journal-title":"Lancet Oncol"},{"key":"R59-20260325","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JTO.0b013e318288ab02","article-title":"Long-term outcome of proton therapy and carbon-ion therapy for large (T2a\u2013T2bN0M0) non\u2013small-cell lung cancer","volume":"8","author":"Iwata","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R60-20260325","doi-asserted-by":"crossref","first-page":"110385","DOI":"10.1016\/j.radonc.2024.110385","article-title":"Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry","volume":"198","author":"Harada","year":"2024","journal-title":"Radiother Oncol"},{"key":"R61-20260325","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2021.1844567","article-title":"Proton therapy for thoracic malignancies: a review of oncologic outcomes","volume":"21","author":"Patel","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"R63-20260325","doi-asserted-by":"crossref","first-page":"e025556","DOI":"10.1136\/bmjopen-2018-025556","article-title":"Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol","volume":"9","author":"Bekelman","year":"2019","journal-title":"BMJ Open"},{"key":"R64-20260325","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(23)00388-1","article-title":"Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial","volume":"24","author":"Mutter","year":"2023","journal-title":"Lancet Oncol"},{"key":"R65-20260325","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.3390\/jcm14103416","article-title":"Partial breast reirradiation for breast cancer recurrences after repeat breast-conserving surgery with proton beam therapy: the prospective BREAST trial (NCT06954623)","volume":"14","author":"Meixner","year":"2025","journal-title":"J Clin Med"},{"key":"R66-20260325","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jrr\/rry113","article-title":"A Phase I clinical trial of carbon ion radiotherapy for stage I breast cancer: clinical and pathological evaluation","volume":"60","author":"Karasawa","year":"2019","journal-title":"J Radiat Res"},{"key":"R67-20260325","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3390\/cancers14123009","article-title":"Exploring the biological and physical basis of boron neutron capture therapy (BNCT) as a promising treatment frontier in breast cancer","volume":"14","author":"Seneviratne","year":"2022","journal-title":"Cancers"},{"key":"R68-20260325","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ijrobp.2025.07.1433","article-title":"Comprehensive analysis of data from a nationwide Japanese cohort on particle therapy for metastatic liver tumors","volume":"123","author":"Fukumitsu","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R69-20260325","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10147-017-1190-2","article-title":"A systematic review of publications on charged particle therapy for hepatocellular carcinoma","volume":"23","author":"Igaki","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"3_suppl","key":"R70-20260325","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.2024.42.3_suppl.480","article-title":"Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial","volume":"42","author":"Ogasawara","year":"2024","journal-title":"J Clin Oncol"},{"key":"R71-20260325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/cancers10030075","article-title":"Stereotactic radiotherapy and particle therapy for pancreatic cancer","volume":"10","author":"Ng","year":"2018","journal-title":"Cancers"},{"issue":"16_suppl","key":"R72-20260325","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1200\/JCO.2022.40.16_suppl.3603","article-title":"Phase 1b\/ 2 study of a radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemo-radiation in locally advanced or unresectable rectal cancer","volume":"40","author":"Huang","journal-title":"J Clin Oncol"},{"key":"R73-20260325","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/17435889.2025.2487411","article-title":"Results of phase Ib\/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer","volume":"20","author":"Huang","year":"2025","journal-title":"Nanomedicine"},{"key":"R74-20260325","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3390\/cancers17162627","article-title":"An in silico feasibility study of dose-escalated hypofractionated proton therapy for rectal cancer","volume":"17","author":"Almhagen","year":"2025","journal-title":"Cancers"},{"key":"R75-20260325","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1159\/000518997","article-title":"Evidence mapping of proton therapy, heavy ion therapy, and helical tomotherapy for gastric cancer","volume":"44","author":"Li","year":"2021","journal-title":"Oncol Res Treat"},{"key":"R76-20260325","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000085","article-title":"Gastrointestinal cancer","volume":"20","author":"Plastaras","year":"2014","journal-title":"Cancer J"},{"key":"R77-20260325","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","article-title":"Prostate advanced radiation technologies investigating quality of life (PARTIQoL): phase III randomized clinical trial of proton therapy vs. IMRT for localized prostate cancer","volume":"120","author":"Efstathiou","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Supplement_1","key":"R78-20260325","doi-asserted-by":"crossref","first-page":"i49","DOI":"10.1093\/jrr\/rrad027","article-title":"Proton beam therapy for muscle-invasive bladder cancer: a systematic review and analysis with Proton-Net, a multicenter prospective patient registry database","volume":"64","author":"Araya","year":"2023","journal-title":"J Radiat Res"},{"key":"R79-20260325","doi-asserted-by":"crossref","first-page":"101259","DOI":"10.1016\/j.adro.2023.101259","article-title":"Cancer control, toxicity, and secondary malignancy risks of proton radiation therapy for stage I-IIB testicular seminoma","volume":"8","author":"Maxwell","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"R80-20260325","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S1470-2045(21)00425-3","article-title":"Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"22","author":"Thariat","year":"2021","journal-title":"Lancet Oncol"},{"key":"R81-20260325","doi-asserted-by":"crossref","first-page":"e2250607","DOI":"10.1001\/jamanetworkopen.2022.50607","article-title":"Evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell carcinoma","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R82-20260325","doi-asserted-by":"crossref","first-page":"131","DOI":"10.14338\/IJPT-20-00064.1","article-title":"A systematic review on re-irradiation with charged particle beam therapy in the management of locally recurrent skull base and head and neck tumors","volume":"8","author":"Gamez","year":"2021","journal-title":"Int J Part Ther"},{"key":"R83-20260325","doi-asserted-by":"crossref","first-page":"e2410670","DOI":"10.1001\/jamanetworkopen.2024.10670","article-title":"Travel-time disparities in access to proton beam therapy for cancer treatment","volume":"7","author":"Burus","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R84-20260325","doi-asserted-by":"crossref","first-page":"pkaf003.","DOI":"10.1093\/jncics\/pkaf003","article-title":"Utilizing proton therapy to reduce health-care disparities among patients with breast cancers","volume":"9","author":"Hsieh","year":"2025","journal-title":"JNCI Cancer Spectrum"},{"key":"R85-20260325","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers16223837","article-title":"Health disparities and inequities in the utilization of proton therapy for prostate cancer","volume":"16","author":"Washington","year":"2024","journal-title":"Cancers"},{"key":"R86-20260325","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/j.clon.2023.05.014","article-title":"Assessing equity of access to proton beam therapy: a literature review","volume":"35","author":"Gaito","year":"2023","journal-title":"Clin Oncol"},{"key":"R87-20260325","doi-asserted-by":"crossref","first-page":"876368","DOI":"10.3389\/fonc.2022.876368","article-title":"Inequality in accessibility of proton therapy for cancers and its economic determinants: a cross-sectional study","volume":"12","author":"Xia","year":"2022","journal-title":"Front Oncol"},{"key":"R88-20260325","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s13246-023-01266-z","article-title":"The current status of FLASH particle therapy: a systematic review","volume":"46","author":"Atkinson","year":"2023","journal-title":"Phys Eng Sci Med"},{"key":"R89-20260325","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1140\/epjti\/s40485-023-00105-5","article-title":"Current development status of accelerator-based neutron source for boron neutron capture therapy","volume":"10","author":"Kumada","year":"2023","journal-title":"EPJ Techn Instrum"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:00:48Z","timestamp":1774450848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000822","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}